nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Dry skin—Doxorubicin—urinary bladder cancer	0.000759	0.000759	CcSEcCtD
Tobramycin—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000757	0.000757	CcSEcCtD
Tobramycin—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000753	0.000753	CcSEcCtD
Tobramycin—Anorexia—Etoposide—urinary bladder cancer	0.000748	0.000748	CcSEcCtD
Tobramycin—Diarrhoea—Thiotepa—urinary bladder cancer	0.000747	0.000747	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000745	0.000745	CcSEcCtD
Tobramycin—Decreased appetite—Cisplatin—urinary bladder cancer	0.000744	0.000744	CcSEcCtD
Tobramycin—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000744	0.000744	CcSEcCtD
Tobramycin—Bronchitis—Epirubicin—urinary bladder cancer	0.000743	0.000743	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000739	0.000739	CcSEcCtD
Tobramycin—Infestation NOS—Methotrexate—urinary bladder cancer	0.000737	0.000737	CcSEcCtD
Tobramycin—Infestation—Methotrexate—urinary bladder cancer	0.000737	0.000737	CcSEcCtD
Tobramycin—Pain—Cisplatin—urinary bladder cancer	0.000732	0.000732	CcSEcCtD
Tobramycin—Muscular weakness—Doxorubicin—urinary bladder cancer	0.00073	0.00073	CcSEcCtD
Tobramycin—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000726	0.000726	CcSEcCtD
Tobramycin—Renal failure—Methotrexate—urinary bladder cancer	0.000724	0.000724	CcSEcCtD
Tobramycin—Dizziness—Thiotepa—urinary bladder cancer	0.000722	0.000722	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000718	0.000718	CcSEcCtD
Tobramycin—Stomatitis—Methotrexate—urinary bladder cancer	0.000718	0.000718	CcSEcCtD
Tobramycin—Urticaria—Fluorouracil—urinary bladder cancer	0.000717	0.000717	CcSEcCtD
Tobramycin—Asthma—Doxorubicin—urinary bladder cancer	0.000715	0.000715	CcSEcCtD
Tobramycin—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000714	0.000714	CcSEcCtD
Tobramycin—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000708	0.000708	CcSEcCtD
Tobramycin—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000705	0.000705	CcSEcCtD
Tobramycin—Paraesthesia—Etoposide—urinary bladder cancer	0.000704	0.000704	CcSEcCtD
Tobramycin—Weight decreased—Epirubicin—urinary bladder cancer	0.000699	0.000699	CcSEcCtD
Tobramycin—Dyspnoea—Etoposide—urinary bladder cancer	0.000699	0.000699	CcSEcCtD
Tobramycin—Epistaxis—Methotrexate—urinary bladder cancer	0.000695	0.000695	CcSEcCtD
Tobramycin—Vomiting—Thiotepa—urinary bladder cancer	0.000694	0.000694	CcSEcCtD
Tobramycin—Infestation—Epirubicin—urinary bladder cancer	0.000689	0.000689	CcSEcCtD
Tobramycin—Infestation NOS—Epirubicin—urinary bladder cancer	0.000689	0.000689	CcSEcCtD
Tobramycin—Rash—Thiotepa—urinary bladder cancer	0.000688	0.000688	CcSEcCtD
Tobramycin—Bronchitis—Doxorubicin—urinary bladder cancer	0.000688	0.000688	CcSEcCtD
Tobramycin—Dermatitis—Thiotepa—urinary bladder cancer	0.000688	0.000688	CcSEcCtD
Tobramycin—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000687	0.000687	CcSEcCtD
Tobramycin—Headache—Thiotepa—urinary bladder cancer	0.000684	0.000684	CcSEcCtD
Tobramycin—Decreased appetite—Etoposide—urinary bladder cancer	0.000682	0.000682	CcSEcCtD
Tobramycin—Renal failure—Epirubicin—urinary bladder cancer	0.000678	0.000678	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000677	0.000677	CcSEcCtD
Tobramycin—Body temperature increased—Cisplatin—urinary bladder cancer	0.000677	0.000677	CcSEcCtD
Tobramycin—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000676	0.000676	CcSEcCtD
Tobramycin—Stomatitis—Epirubicin—urinary bladder cancer	0.000672	0.000672	CcSEcCtD
Tobramycin—Pain—Etoposide—urinary bladder cancer	0.000671	0.000671	CcSEcCtD
Tobramycin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000665	0.000665	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000665	0.000665	CcSEcCtD
Tobramycin—Asthenia—Gemcitabine—urinary bladder cancer	0.000659	0.000659	CcSEcCtD
Tobramycin—Pharyngitis—Methotrexate—urinary bladder cancer	0.000656	0.000656	CcSEcCtD
Tobramycin—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000653	0.000653	CcSEcCtD
Tobramycin—Epistaxis—Epirubicin—urinary bladder cancer	0.00065	0.00065	CcSEcCtD
Tobramycin—Pruritus—Gemcitabine—urinary bladder cancer	0.00065	0.00065	CcSEcCtD
Tobramycin—Nausea—Thiotepa—urinary bladder cancer	0.000648	0.000648	CcSEcCtD
Tobramycin—Urethral disorder—Methotrexate—urinary bladder cancer	0.000648	0.000648	CcSEcCtD
Tobramycin—Weight decreased—Doxorubicin—urinary bladder cancer	0.000647	0.000647	CcSEcCtD
Tobramycin—Sinusitis—Epirubicin—urinary bladder cancer	0.000647	0.000647	CcSEcCtD
Tobramycin—Feeling abnormal—Etoposide—urinary bladder cancer	0.000646	0.000646	CcSEcCtD
Tobramycin—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000643	0.000643	CcSEcCtD
Tobramycin—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000641	0.000641	CcSEcCtD
Tobramycin—Pruritus—Fluorouracil—urinary bladder cancer	0.000639	0.000639	CcSEcCtD
Tobramycin—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000638	0.000638	CcSEcCtD
Tobramycin—Infestation—Doxorubicin—urinary bladder cancer	0.000638	0.000638	CcSEcCtD
Tobramycin—Visual impairment—Methotrexate—urinary bladder cancer	0.000637	0.000637	CcSEcCtD
Tobramycin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000631	0.000631	CcSEcCtD
Tobramycin—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000628	0.000628	CcSEcCtD
Tobramycin—Renal failure—Doxorubicin—urinary bladder cancer	0.000627	0.000627	CcSEcCtD
Tobramycin—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000625	0.000625	CcSEcCtD
Tobramycin—Urticaria—Etoposide—urinary bladder cancer	0.000623	0.000623	CcSEcCtD
Tobramycin—Stomatitis—Doxorubicin—urinary bladder cancer	0.000622	0.000622	CcSEcCtD
Tobramycin—Rhinitis—Epirubicin—urinary bladder cancer	0.00062	0.00062	CcSEcCtD
Tobramycin—Abdominal pain—Etoposide—urinary bladder cancer	0.00062	0.00062	CcSEcCtD
Tobramycin—Body temperature increased—Etoposide—urinary bladder cancer	0.00062	0.00062	CcSEcCtD
Tobramycin—Eye disorder—Methotrexate—urinary bladder cancer	0.000618	0.000618	CcSEcCtD
Tobramycin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000618	0.000618	CcSEcCtD
Tobramycin—Tinnitus—Methotrexate—urinary bladder cancer	0.000616	0.000616	CcSEcCtD
Tobramycin—Asthenia—Cisplatin—urinary bladder cancer	0.000614	0.000614	CcSEcCtD
Tobramycin—Pharyngitis—Epirubicin—urinary bladder cancer	0.000614	0.000614	CcSEcCtD
Tobramycin—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000611	0.000611	CcSEcCtD
Tobramycin—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000608	0.000608	CcSEcCtD
Tobramycin—Urethral disorder—Epirubicin—urinary bladder cancer	0.000607	0.000607	CcSEcCtD
Tobramycin—Epistaxis—Doxorubicin—urinary bladder cancer	0.000602	0.000602	CcSEcCtD
Tobramycin—Angiopathy—Methotrexate—urinary bladder cancer	0.0006	0.0006	CcSEcCtD
Tobramycin—Sinusitis—Doxorubicin—urinary bladder cancer	0.000598	0.000598	CcSEcCtD
Tobramycin—Immune system disorder—Methotrexate—urinary bladder cancer	0.000597	0.000597	CcSEcCtD
Tobramycin—Dizziness—Fluorouracil—urinary bladder cancer	0.000597	0.000597	CcSEcCtD
Tobramycin—Visual impairment—Epirubicin—urinary bladder cancer	0.000596	0.000596	CcSEcCtD
Tobramycin—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000596	0.000596	CcSEcCtD
Tobramycin—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000595	0.000595	CcSEcCtD
Tobramycin—Diarrhoea—Cisplatin—urinary bladder cancer	0.000586	0.000586	CcSEcCtD
Tobramycin—Vomiting—Gemcitabine—urinary bladder cancer	0.000584	0.000584	CcSEcCtD
Tobramycin—Rash—Gemcitabine—urinary bladder cancer	0.000579	0.000579	CcSEcCtD
Tobramycin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000579	0.000579	CcSEcCtD
Tobramycin—Eye disorder—Epirubicin—urinary bladder cancer	0.000578	0.000578	CcSEcCtD
Tobramycin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000578	0.000578	CcSEcCtD
Tobramycin—Tinnitus—Epirubicin—urinary bladder cancer	0.000577	0.000577	CcSEcCtD
Tobramycin—Erythema—Methotrexate—urinary bladder cancer	0.000576	0.000576	CcSEcCtD
Tobramycin—Headache—Gemcitabine—urinary bladder cancer	0.000575	0.000575	CcSEcCtD
Tobramycin—Vomiting—Fluorouracil—urinary bladder cancer	0.000574	0.000574	CcSEcCtD
Tobramycin—Rhinitis—Doxorubicin—urinary bladder cancer	0.000574	0.000574	CcSEcCtD
Tobramycin—Rash—Fluorouracil—urinary bladder cancer	0.000569	0.000569	CcSEcCtD
Tobramycin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000569	0.000569	CcSEcCtD
Tobramycin—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000568	0.000568	CcSEcCtD
Tobramycin—Headache—Fluorouracil—urinary bladder cancer	0.000566	0.000566	CcSEcCtD
Tobramycin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000565	0.000565	CcSEcCtD
Tobramycin—Dysgeusia—Methotrexate—urinary bladder cancer	0.000564	0.000564	CcSEcCtD
Tobramycin—Asthenia—Etoposide—urinary bladder cancer	0.000563	0.000563	CcSEcCtD
Tobramycin—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000563	0.000563	CcSEcCtD
Tobramycin—Angiopathy—Epirubicin—urinary bladder cancer	0.000561	0.000561	CcSEcCtD
Tobramycin—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000561	0.000561	CcSEcCtD
Tobramycin—Immune system disorder—Epirubicin—urinary bladder cancer	0.000559	0.000559	CcSEcCtD
Tobramycin—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000558	0.000558	CcSEcCtD
Tobramycin—Back pain—Methotrexate—urinary bladder cancer	0.000557	0.000557	CcSEcCtD
Tobramycin—Pruritus—Etoposide—urinary bladder cancer	0.000555	0.000555	CcSEcCtD
Tobramycin—Visual impairment—Doxorubicin—urinary bladder cancer	0.000552	0.000552	CcSEcCtD
Tobramycin—Nausea—Gemcitabine—urinary bladder cancer	0.000546	0.000546	CcSEcCtD
Tobramycin—Vomiting—Cisplatin—urinary bladder cancer	0.000544	0.000544	CcSEcCtD
Tobramycin—Vision blurred—Methotrexate—urinary bladder cancer	0.000542	0.000542	CcSEcCtD
Tobramycin—Rash—Cisplatin—urinary bladder cancer	0.00054	0.00054	CcSEcCtD
Tobramycin—Dermatitis—Cisplatin—urinary bladder cancer	0.000539	0.000539	CcSEcCtD
Tobramycin—Erythema—Epirubicin—urinary bladder cancer	0.000539	0.000539	CcSEcCtD
Tobramycin—Diarrhoea—Etoposide—urinary bladder cancer	0.000537	0.000537	CcSEcCtD
Tobramycin—Nausea—Fluorouracil—urinary bladder cancer	0.000536	0.000536	CcSEcCtD
Tobramycin—Eye disorder—Doxorubicin—urinary bladder cancer	0.000535	0.000535	CcSEcCtD
Tobramycin—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000534	0.000534	CcSEcCtD
Tobramycin—Tinnitus—Doxorubicin—urinary bladder cancer	0.000534	0.000534	CcSEcCtD
Tobramycin—Anaemia—Methotrexate—urinary bladder cancer	0.000532	0.000532	CcSEcCtD
Tobramycin—Dysgeusia—Epirubicin—urinary bladder cancer	0.000527	0.000527	CcSEcCtD
Tobramycin—Back pain—Epirubicin—urinary bladder cancer	0.000521	0.000521	CcSEcCtD
Tobramycin—Angiopathy—Doxorubicin—urinary bladder cancer	0.000519	0.000519	CcSEcCtD
Tobramycin—Malaise—Methotrexate—urinary bladder cancer	0.000519	0.000519	CcSEcCtD
Tobramycin—Dizziness—Etoposide—urinary bladder cancer	0.000519	0.000519	CcSEcCtD
Tobramycin—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000517	0.000517	CcSEcCtD
Tobramycin—Vertigo—Methotrexate—urinary bladder cancer	0.000517	0.000517	CcSEcCtD
Tobramycin—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000516	0.000516	CcSEcCtD
Tobramycin—Leukopenia—Methotrexate—urinary bladder cancer	0.000515	0.000515	CcSEcCtD
Tobramycin—Nausea—Cisplatin—urinary bladder cancer	0.000508	0.000508	CcSEcCtD
Tobramycin—Vision blurred—Epirubicin—urinary bladder cancer	0.000508	0.000508	CcSEcCtD
Tobramycin—Cough—Methotrexate—urinary bladder cancer	0.000502	0.000502	CcSEcCtD
Tobramycin—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.0005	0.0005	CcSEcCtD
Tobramycin—Vomiting—Etoposide—urinary bladder cancer	0.000499	0.000499	CcSEcCtD
Tobramycin—Erythema—Doxorubicin—urinary bladder cancer	0.000498	0.000498	CcSEcCtD
Tobramycin—Anaemia—Epirubicin—urinary bladder cancer	0.000498	0.000498	CcSEcCtD
Tobramycin—Rash—Etoposide—urinary bladder cancer	0.000494	0.000494	CcSEcCtD
Tobramycin—Dermatitis—Etoposide—urinary bladder cancer	0.000494	0.000494	CcSEcCtD
Tobramycin—Headache—Etoposide—urinary bladder cancer	0.000491	0.000491	CcSEcCtD
Tobramycin—Myalgia—Methotrexate—urinary bladder cancer	0.00049	0.00049	CcSEcCtD
Tobramycin—Chest pain—Methotrexate—urinary bladder cancer	0.00049	0.00049	CcSEcCtD
Tobramycin—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000488	0.000488	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000487	0.000487	CcSEcCtD
Tobramycin—Malaise—Epirubicin—urinary bladder cancer	0.000486	0.000486	CcSEcCtD
Tobramycin—Discomfort—Methotrexate—urinary bladder cancer	0.000484	0.000484	CcSEcCtD
Tobramycin—Vertigo—Epirubicin—urinary bladder cancer	0.000484	0.000484	CcSEcCtD
Tobramycin—Leukopenia—Epirubicin—urinary bladder cancer	0.000482	0.000482	CcSEcCtD
Tobramycin—Back pain—Doxorubicin—urinary bladder cancer	0.000482	0.000482	CcSEcCtD
Tobramycin—Confusional state—Methotrexate—urinary bladder cancer	0.000474	0.000474	CcSEcCtD
Tobramycin—Cough—Epirubicin—urinary bladder cancer	0.00047	0.00047	CcSEcCtD
Tobramycin—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00047	0.00047	CcSEcCtD
Tobramycin—Vision blurred—Doxorubicin—urinary bladder cancer	0.00047	0.00047	CcSEcCtD
Tobramycin—Nausea—Etoposide—urinary bladder cancer	0.000466	0.000466	CcSEcCtD
Tobramycin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000462	0.000462	CcSEcCtD
Tobramycin—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000461	0.000461	CcSEcCtD
Tobramycin—Anaemia—Doxorubicin—urinary bladder cancer	0.000461	0.000461	CcSEcCtD
Tobramycin—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00046	0.00046	CcSEcCtD
Tobramycin—Chest pain—Epirubicin—urinary bladder cancer	0.000459	0.000459	CcSEcCtD
Tobramycin—Myalgia—Epirubicin—urinary bladder cancer	0.000459	0.000459	CcSEcCtD
Tobramycin—Skin disorder—Methotrexate—urinary bladder cancer	0.000456	0.000456	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000455	0.000455	CcSEcCtD
Tobramycin—Discomfort—Epirubicin—urinary bladder cancer	0.000453	0.000453	CcSEcCtD
Tobramycin—Malaise—Doxorubicin—urinary bladder cancer	0.000449	0.000449	CcSEcCtD
Tobramycin—Vertigo—Doxorubicin—urinary bladder cancer	0.000448	0.000448	CcSEcCtD
Tobramycin—Anorexia—Methotrexate—urinary bladder cancer	0.000448	0.000448	CcSEcCtD
Tobramycin—Leukopenia—Doxorubicin—urinary bladder cancer	0.000446	0.000446	CcSEcCtD
Tobramycin—Confusional state—Epirubicin—urinary bladder cancer	0.000443	0.000443	CcSEcCtD
Tobramycin—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00044	0.00044	CcSEcCtD
Tobramycin—Cough—Doxorubicin—urinary bladder cancer	0.000435	0.000435	CcSEcCtD
Tobramycin—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000431	0.000431	CcSEcCtD
Tobramycin—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00043	0.00043	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000428	0.000428	CcSEcCtD
Tobramycin—Skin disorder—Epirubicin—urinary bladder cancer	0.000427	0.000427	CcSEcCtD
Tobramycin—Myalgia—Doxorubicin—urinary bladder cancer	0.000424	0.000424	CcSEcCtD
Tobramycin—Chest pain—Doxorubicin—urinary bladder cancer	0.000424	0.000424	CcSEcCtD
Tobramycin—Paraesthesia—Methotrexate—urinary bladder cancer	0.000422	0.000422	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000421	0.000421	CcSEcCtD
Tobramycin—Discomfort—Doxorubicin—urinary bladder cancer	0.000419	0.000419	CcSEcCtD
Tobramycin—Anorexia—Epirubicin—urinary bladder cancer	0.000419	0.000419	CcSEcCtD
Tobramycin—Dyspnoea—Methotrexate—urinary bladder cancer	0.000419	0.000419	CcSEcCtD
Tobramycin—Confusional state—Doxorubicin—urinary bladder cancer	0.00041	0.00041	CcSEcCtD
Tobramycin—Decreased appetite—Methotrexate—urinary bladder cancer	0.000408	0.000408	CcSEcCtD
Tobramycin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000407	0.000407	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000406	0.000406	CcSEcCtD
Tobramycin—Pain—Methotrexate—urinary bladder cancer	0.000402	0.000402	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000401	0.000401	CcSEcCtD
Tobramycin—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000399	0.000399	CcSEcCtD
Tobramycin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000398	0.000398	CcSEcCtD
Tobramycin—Skin disorder—Doxorubicin—urinary bladder cancer	0.000395	0.000395	CcSEcCtD
Tobramycin—Paraesthesia—Epirubicin—urinary bladder cancer	0.000395	0.000395	CcSEcCtD
Tobramycin—Dyspnoea—Epirubicin—urinary bladder cancer	0.000392	0.000392	CcSEcCtD
Tobramycin—Anorexia—Doxorubicin—urinary bladder cancer	0.000388	0.000388	CcSEcCtD
Tobramycin—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000387	0.000387	CcSEcCtD
Tobramycin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000384	0.000384	CcSEcCtD
Tobramycin—Decreased appetite—Epirubicin—urinary bladder cancer	0.000382	0.000382	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00038	0.00038	CcSEcCtD
Tobramycin—Pain—Epirubicin—urinary bladder cancer	0.000376	0.000376	CcSEcCtD
Tobramycin—Urticaria—Methotrexate—urinary bladder cancer	0.000373	0.000373	CcSEcCtD
Tobramycin—Abdominal pain—Methotrexate—urinary bladder cancer	0.000371	0.000371	CcSEcCtD
Tobramycin—Body temperature increased—Methotrexate—urinary bladder cancer	0.000371	0.000371	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000371	0.000371	CcSEcCtD
Tobramycin—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000365	0.000365	CcSEcCtD
Tobramycin—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000363	0.000363	CcSEcCtD
Tobramycin—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000362	0.000362	CcSEcCtD
Tobramycin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000359	0.000359	CcSEcCtD
Tobramycin—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000354	0.000354	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000351	0.000351	CcSEcCtD
Tobramycin—Urticaria—Epirubicin—urinary bladder cancer	0.000349	0.000349	CcSEcCtD
Tobramycin—Pain—Doxorubicin—urinary bladder cancer	0.000348	0.000348	CcSEcCtD
Tobramycin—Abdominal pain—Epirubicin—urinary bladder cancer	0.000348	0.000348	CcSEcCtD
Tobramycin—Body temperature increased—Epirubicin—urinary bladder cancer	0.000348	0.000348	CcSEcCtD
Tobramycin—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000346	0.000346	CcSEcCtD
Tobramycin—Asthenia—Methotrexate—urinary bladder cancer	0.000337	0.000337	CcSEcCtD
Tobramycin—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000335	0.000335	CcSEcCtD
Tobramycin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000333	0.000333	CcSEcCtD
Tobramycin—Pruritus—Methotrexate—urinary bladder cancer	0.000332	0.000332	CcSEcCtD
Tobramycin—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000324	0.000324	CcSEcCtD
Tobramycin—Urticaria—Doxorubicin—urinary bladder cancer	0.000323	0.000323	CcSEcCtD
Tobramycin—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000322	0.000322	CcSEcCtD
Tobramycin—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000322	0.000322	CcSEcCtD
Tobramycin—Diarrhoea—Methotrexate—urinary bladder cancer	0.000321	0.000321	CcSEcCtD
Tobramycin—Asthenia—Epirubicin—urinary bladder cancer	0.000315	0.000315	CcSEcCtD
Tobramycin—Pruritus—Epirubicin—urinary bladder cancer	0.000311	0.000311	CcSEcCtD
Tobramycin—Dizziness—Methotrexate—urinary bladder cancer	0.000311	0.000311	CcSEcCtD
Tobramycin—Diarrhoea—Epirubicin—urinary bladder cancer	0.000301	0.000301	CcSEcCtD
Tobramycin—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.0003	0.0003	CcSEcCtD
Tobramycin—Vomiting—Methotrexate—urinary bladder cancer	0.000299	0.000299	CcSEcCtD
Tobramycin—Rash—Methotrexate—urinary bladder cancer	0.000296	0.000296	CcSEcCtD
Tobramycin—Dermatitis—Methotrexate—urinary bladder cancer	0.000296	0.000296	CcSEcCtD
Tobramycin—Headache—Methotrexate—urinary bladder cancer	0.000294	0.000294	CcSEcCtD
Tobramycin—Asthenia—Doxorubicin—urinary bladder cancer	0.000292	0.000292	CcSEcCtD
Tobramycin—Dizziness—Epirubicin—urinary bladder cancer	0.000291	0.000291	CcSEcCtD
Tobramycin—Pruritus—Doxorubicin—urinary bladder cancer	0.000288	0.000288	CcSEcCtD
Tobramycin—Vomiting—Epirubicin—urinary bladder cancer	0.00028	0.00028	CcSEcCtD
Tobramycin—Nausea—Methotrexate—urinary bladder cancer	0.000279	0.000279	CcSEcCtD
Tobramycin—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000278	0.000278	CcSEcCtD
Tobramycin—Rash—Epirubicin—urinary bladder cancer	0.000277	0.000277	CcSEcCtD
Tobramycin—Dermatitis—Epirubicin—urinary bladder cancer	0.000277	0.000277	CcSEcCtD
Tobramycin—Headache—Epirubicin—urinary bladder cancer	0.000275	0.000275	CcSEcCtD
Tobramycin—Dizziness—Doxorubicin—urinary bladder cancer	0.000269	0.000269	CcSEcCtD
Tobramycin—Nausea—Epirubicin—urinary bladder cancer	0.000261	0.000261	CcSEcCtD
Tobramycin—Vomiting—Doxorubicin—urinary bladder cancer	0.000259	0.000259	CcSEcCtD
Tobramycin—Rash—Doxorubicin—urinary bladder cancer	0.000256	0.000256	CcSEcCtD
Tobramycin—Dermatitis—Doxorubicin—urinary bladder cancer	0.000256	0.000256	CcSEcCtD
Tobramycin—Headache—Doxorubicin—urinary bladder cancer	0.000255	0.000255	CcSEcCtD
Tobramycin—Nausea—Doxorubicin—urinary bladder cancer	0.000242	0.000242	CcSEcCtD
